依达拉奉联合血栓通对急性脑梗死患者血流变学的影响

目的分析依达拉奉联合血栓通对急性脑梗死患者血流变学的影响,探讨其临床适用性。方法选择2013-05—2014-05于我院就诊的60例急性脑梗死患者,随机分为试验组30例和对照组30例,对照组采用血栓通治疗,试验组在对照组基础上联合依达拉奉进行治疗。观察2组治疗前后NIHSS评分、血脂水平和凝血指标、血液流变学指标的变化情况及治疗后临床疗效。结果治疗前2组NIHSS评分、血脂水平和凝血情况、血流变学相关指标水平比较无明显差异(P0.05),治疗后2组的NIHSS评分、血脂水平和凝血情况、血流变学相关指标水平均明显降低(P0.05),且试验组改善情况优于对照组(P0.05);试验组总有效率为93.33%(28/30),对照组为73.33%(22/30),差异有统计学意义(χ2=4.320 0,P=0.037 7)。2组治疗过程中未出现明显不良反应。结论依达拉奉联合血栓通治疗急性脑梗死安全有效,可有效改善患者的血脂和血流变,降低病情进展危险因素。

The effects of edaravone uniting Xueshuantong on hemorheology in acute cerebral infarction patients

Objective To analyze the effects of edaravone plus Xueshuantong on hemorheology in acute cerebral infarction patients.Methods Sixty cases with acute cerebral infarction were selected from May 2013 to May 2014 in our hospital.And they were randomly divided into study group(30 cases)and control group(30 cases).The Xueshuantong treatment was applied in the control group and the combination therapy of edaravone and Xueshuantong was applied in the study group.Finally,we observed the NIHSS scores,serum lipid level,coagulation indicators,blood hemorheological indicators and clinical efficacy after treatment be-tween the two groups.Results Before treatment,no significant differences were found between two groups in NIHSS scores,ser-um lipid level,coagulation indicators and blood hemorheological indicators(all P>0.05),but which were obviously decreased after treatment(all P<0.05),and the study group showed better improvement than the control group(P<0.05).The total effective rate of the study group was 93.33%(28/30),significantly higher than 73.33%(22/30)in the control group(χ2=4.3200,P =0.037 7).No remarkable adverse events occurred in both two groups.Conclusion The therapy of edaravone plus Xueshuantong in the treatment of acute cerebral infarction is safe and effective,it can effectively improve serum lipid level and blood hemorheologi-cal indicators and reduce the risk factors for disease ro ression.